Ranitidine Market Research Report By Type of Ranitidine (Tablet, Injection, Suspension), By Application (Gastric Ulcer and Duodenal Ulcer, GERD and Peptic Ulcer Disease, Zollinger-Ellison Syndrome), By Grade (Pharmaceutical Grade, Medical Grade, Food Grade), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Dealers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Global Ranitidine Market Overview

As per MRFR analysis, the Ranitidine Market Size was estimated at 1.27 (USD Billion) in 2022. The Ranitidine Industry is expected to grow from 1.31 (USD Billion) in 2023 to 1.77 (USD Billion) by 2032. The Ranitidine Market CAGR (growth rate) is expected to be around 3.37% during the forecast period (2024 - 2032).

Key Ranitidine Market Trends Highlighted

Key market drivers for the Ranitidine market include the rising prevalence of gastrointestinal diseases, such as gastroesophageal reflux disease (GERD) and peptic ulcers, as well as the increasing demand for effective and affordable medications to treat these conditions. 

Additionally, the growing geriatric population, which is more susceptible to gastrointestinal disorders, is expected to further drive market growth.Opportunities for exploration and capture in the Ranitidine market lie in the development of novel formulations and delivery systems that improve drug efficacy and reduce side effects. 

Furthermore, the expansion into emerging markets, where access to healthcare is limited, presents significant growth potential.Recent trends in the Ranitidine market include the emergence of generic formulations, which have led to increased competition and lower prices. Moreover, the growing adoption of over-the-counter (OTC) Ranitidine products has expanded market reach and convenience. 

However, regulatory scrutiny and safety concerns related to Ranitidine's potential carcinogenic effects may present challenges to the market's continued growth.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Ranitidine Market Drivers

Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)

Gastroesophageal reflux disease (GERD) is a recurrent disorder common in individuals that occurs when gastric acid leaks back into the esophagus. Symptoms will include heartburn, some regurgitation, along with some other unpleasant manifestations. Ranitidine is a medication that is used to treat GERD by reducing the production of stomach acid. 

The increasing prevalence of GERD is a major driver of the growth of the Ranitidine Market Industry. According to the International Foundation for Gastrointestinal Disorders, GERD affects approximately 20% of the global population.

This number is expected to increase in the coming years due to factors such as rising obesity rates, changes in dietary habits and the aging population. As the prevalence of GERD increases, the demand for ranitidine is also expected to grow.

Growing Demand for Over-the-Counter (OTC) Medications

Ranitidine is available both by prescription and over-the-counter (OTC). OTC medications are those that can be purchased without a prescription. The growing demand for OTC medications is a major driver of the growth of the Ranitidine Industry. This is due to the fact that OTC medications are more convenient and affordable than prescription medications. As more and more people choose to self-medicate for minor ailments, the demand for OTC ranitidine is expected to grow.

Rising Healthcare Expenditure

One more important factor that has been driving the growth of the Ranitidine Market Industry is the increasing healthcare expenditure. It happens since ranitidine is a relatively cheap medication. Nowadays, people prefer to purchase not expensive drugs, and the prohibitive costs of health care remain one of the topical issues. 

Ranitidine is used for the treatment of GERD and some other conditions. As a result, the drug is rather in demand, and the mentioned factors can be attributed to the main ones for driving the industry’s growth.

Ranitidine Market Segment Insights

Ranitidine Type of Ranitidine Insights

Type of Ranitidine Ranitidine is available in various forms, including tablets, injections, and suspensions, each designed to meet the specific needs of patients. Tablets are the most commonly used form of ranitidine, accounting for a significant share of the Ranitidine Market revenue. This growth is primarily attributed to the increasing prevalence of acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcer disease, and the efficacy of ranitidine in managing these conditions. Injections of ranitidine are another important segment of the Ranitidine Market.

Ranitidine injections are typically used in hospital settings for patients who are unable to take oral medications or in emergency situations. The market for ranitidine injections is expected to witness steady growth in the coming years, driven by the increasing demand for injectable medications in hospitals and clinics. Suspensions of ranitidine are also available, which are particularly suitable for pediatric patients and individuals who have difficulty swallowing tablets. 

The market for ranitidine suspensions is expected to grow at a moderate pace, supported by the increasing awareness of acid-related disorders among parents and healthcare professionals. Overall, the Ranitidine Market is expected to continue to grow in the coming years, driven by the increasing prevalence of acid-related disorders, the efficacy of ranitidine in managing these conditions, and the availability of various formulations to meet the specific needs of patients.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Ranitidine Application Insights

The Ranitidine Market revenue for the application segment is expected to witness steady growth over the forecast period. In 2023, the Gastric Ulcer and Duodenal Ulcer sub-segment held the largest market share. Ranitidine is a medication used to treat and prevent various conditions that involve excessive production of stomach acids, such as gastric ulcers and duodenal ulcers. It exerts its action by blocking histamine H2 receptors in the stomach, thereby reducing gastric acid secretion. 

GERD and Peptic Ulcer Disease is another major application segment of the Ranitidine Market. Ranitidine is effective in reducing symptoms of GERD, such as heartburn and acid reflux. It also helps to heal ulcers in the esophagus and stomach, which are caused by excessive acid production. Zollinger-Ellison Syndrome is a rare condition characterized by excessive production of stomach acid. Ranitidine is one of the medications used to control stomach acid secretion in patients with Zollinger-Ellison Syndrome. 

Overall, the Ranitidine Market is expected to grow steadily over the forecast period, driven by the increasing prevalence of gastric ulcers, duodenal ulcers, GERD, and Zollinger-Ellison Syndrome.

Ranitidine Grade Insights

The Ranitidine Market is segmented by Grade into Pharmaceutical Grade, Medical Grade, and Food Grade. Among these segments, the Pharmaceutical Grade segment is expected to hold the largest market share in 2023, owing to the increasing demand for Ranitidine in the production of various pharmaceutical formulations. 

The Medical Grade segment is also expected to witness significant growth during the forecast period due to the rising prevalence of gastric disorders and the growing demand for Ranitidine in hospitals and clinics. The food-grade segment is expected to hold a relatively smaller market share, but it is projected to grow at a steady pace during the forecast period, driven by the increasing demand for Ranitidine in the food industry as a preservative and antioxidant.

Ranitidine Distribution Channel Insights

The Ranitidine Market segmentation by Distribution Channel comprises Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Wholesale Dealers. Among these, Hospital Pharmacies accounted for the largest market share in 2023, owing to the high volume of Ranitidine prescriptions dispensed in hospitals. 

Retail Pharmacies follow next, driven by the convenience and accessibility they offer to patients. Online Pharmacies are gaining traction due to the growing adoption of e-commerce and the ease of ordering medications online. Wholesale Dealers play a crucial role in the distribution of Ranitidine to various pharmacies and healthcare providers.

The Ranitidine Market revenue from the Distribution Channel segment is projected to reach USD 1.31 billion in 2023, exhibiting a CAGR of 3.37% during the forecast period 2023-2032, driven by the increasing prevalence of gastric disorders and the rising demand for Ranitidine as a cost-effective treatment option.

Ranitidine Regional Insights

The Ranitidine Market is segmented into North America, Europe, APAC, South America and MEA. North America dominated the market in 2023 and is expected to retain its dominance throughout the forecast period. The Ranitidine Market in North America is driven by the increasing prevalence of gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD). 

Europe is the second largest market for ranitidine. The market in Europe is expected to grow at a CAGR of 3.3% during the forecast period. The growth of the market in Europe is attributed to the increasing awareness of GERD and PUD, as well as the growing adoption of proton pump inhibitors (PPIs).The APAC region is the fastest-growing market for ranitidine. 

The market in APAC is expected to grow at a CAGR of 4.1% during the forecast period. The growth of the market in APAC is attributed to the increasing prevalence of GERD and PUD, as well as the growing population in the region. 

South America and MEA are relatively smaller markets for ranitidine. However, the market in these regions is expected to grow at a CAGR of 3.5% and 3.8%, respectively, during the forecast period. The growth of the market in South America and MEA is attributed to the increasing prevalence of GERD and PUD, as well as the growing population in these regions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Ranitidine Market Key Players And Competitive Insights:

The major players in the Ranitidine Market are primarily focusing on expanding product output through product portfolio expansion, expansion in new markets, and partnerships and takeovers among key global players. 

For instance, in May 2021, Guilin Guokai Pharmaceutical Co., Ltd. had its efforts rewarded when China’s National Medical Products Administration finally approved the company’s application to market and sell its generic Ranitidine Hydrochloride Injection in China. At the same time, the company confirmed that its application to market the product in the major developed countries is at the final stage. This expansion enhances the company’s competitiveness in the global market. 

In addition, the product output is expanding through heavy investment in research and development to create new products and new technologies. Formulations and technologies at the Ranitidine Market Development Pipeline have new delivery systems, combined products, and new formulations to enhance patient care. 

GSK is a major player in the Ranitidine industry. The company has an established brand name and a strong international presence. GlaxoSmithKline’s Ranitidine products are branded Zantac. The company has an extensive range of Ranitidine products, including tablets, injections, and oral syrup. Moreover, GlaxoSmithKline is also involved in research and development to create better products and new Ranitidine products.AstraZeneca plc is a major player in the Ranitidine Market. 

The company has a strong presence in Europe and Asia. AstraZeneca’s Ranitidine products are branded Pepcid. Moreover, the company has an extensive Ranitidine product line, including tablets, injections, and oral suspensions. At the same time, AstraZeneca is also involved in research and development to create better and new Ranitidine products.

Key Companies in the Ranitidine Market Include:

• Novartis AG


• Johnson Johnson


• Lupin Limited


• Teva Pharmaceutical Industries Ltd.


• Boehringer Ingelheim


• Mylan N.V.


• Sanofi


• Sun Pharmaceutical Industries Ltd.


• GlaxoSmithKline


• Bristol Myers Squibb


• Cipla Ltd.


• Pfizer Inc.


• Abbott Laboratories


• Merck Co., Inc.

Ranitidine Market Industry Developments

The Ranitidine market is expected to grow from USD 1.31 billion in 2023 to USD 1.77 billion by 2032, at a CAGR of 3.37% during the forecast period. The growth of the market is attributed to the increasing prevalence of gastroesophageal reflux disease (GERD) and peptic ulcer disease, as well as the rising demand for over-the-counter (OTC) antacids.

Recent news developments in the market include the launch of new Ranitidine products by various pharmaceutical companies. For instance, in 2023, Glenmark Pharmaceuticals launched a new OTC Ranitidine product under the brand name Zantac OTC. The product is available in both tablet and liquid form and is indicated for the treatment of heartburn, acid indigestion, and sour stomach.Another key trend in the market is the growing adoption of biosimilars. 

Biosimilars are similar to brand-name drugs but are developed and manufactured by different companies. They are typically less expensive than brand-name drugs and offer similar efficacy and safety. Several Ranitidine biosimilars have been approved by regulatory authorities in recent years, and their adoption is expected to further drive market growth.

Ranitidine Market Segmentation

Ranitidine Type of Ranitidine Outlook

• Tablet


• Injection


• Suspension

Ranitidine Application Outlook

• Gastric Ulcer and Duodenal Ulcer


• GERD and Peptic Ulcer Disease


• Zollinger-Ellison Syndrome

Ranitidine Grade Outlook

• Pharmaceutical Grade


• Medical Grade


• Food Grade

Ranitidine Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies


• Wholesale Dealers

Ranitidine Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa